A federal consultative group voted Thursday to loosen rules on seven peptides, including BPC-157 and TB-500. The vote was close. It is advisory only. The FDA has given no indication on whether it will follow the advice. The move came after weeks of public hearings. Wellness backers pressed firmly for wider access. RFK Jr. was among them. Critics say these compounds have little hard evidence of safety or help for most uses. The call could redefine how the agency handles a part of the wellness market that is surging ahead. Patient groups are waiting to see if the FDA picks up the plan. A spokesperson offered no firm timeline for a follow-up. Wellness voices argue the change would broaden access to products that users favor. Health groups warn that looser rules could open the door to misuse across a quickly growing market. The committee vote only lays the groundwork for change, and the final call rests with the federal agency.